Bioequivalence Requirements Could Be Reduced By Question-Based Review
Executive Summary
A question-based review emphasizing quality by design could reduce the need to conduct bioequivalence studies for highly variable drugs, FDA said at a meeting of the Advisory Committee for Pharmaceutical Science on May 4
You may also be interested in...
Biowaivers Proposed For Highly Permeable, Soluble, Rapidly Dissolving Drugs
FDA is proposing to grant waivers of in vivo bioequivalence tests for certain immediate-release solid oral dosage form drugs that meet the characteristics of being highly permeable, soluble and having rapid dissolution.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials